Previous studies have shown that HER2 expression becomes negative in patients with HER2-positive breast cancer after neoadjuvant treatment, and the negative conversion rate of HER2 expression ranges from 9.4% to 40%. This evidence concerns the gene ERBB2 and breast carcinoma.